Loading...

Bluepharma opens an industrial unit unique in Portugal and one of the largest in Europe

ONConcept March 2023

Bluepharma Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area. The investment amounts to 30 million euros and results in a unique plant in Portugal and one of the largest in Europe for the production of medicines with these specifications. This new unit in Eiras, Coimbra, creates 100 jobs, most of them highly qualified.

The ceremony´s launch was attended by several national and international entities and partners, as the Portuguese Minister of Economy and Sea, António Costa Silva, the President of Medicines for Europe, Elisabeth Stampa, and the President of Bluepharma, Paulo Barradas Rebelo.

This production unit materializes the ONConcept® project, which brought Bluepharma together in a partnership with two German companies of reference in the pharmaceutical area - Helm and Welding.

A reliable, flexible, and high-quality European partnership able to serve global markets with differentiated, high-value medicines. This new unit represents an important role to Europe's reindustrialization strategy, while being an important contribution to the sustainability of the health systems and accessibility of life-changing medicines to patients, namely in oncology.

Portugal-based Bluepharma operates as a CDMO with all the capabilities needed to offer an integrated approach from development to commercial manufacturing. Together with the German partners Helm and Welding, the collaboration bundles its scientific and regulatory knowledge, enlarges the API sourcing network, offers its own intellectual property service, strengthens the individual market knowledge and access to realize a strong highly potent products’ portfolio made in Europe.

Currently the ONConcept® project had built a basket of more than 20 products. The composition of the portfolio positions ONConcept® to provide a steady stream of new opportunities to its partners, with some of the molecules open to off-patent competition today and others having LoE dates for later in the decade.

In the coming years, the strategic alliance wants to become known as a reputable European supplier of highly potent drugs with the capabilities needed to develop, register, and supply complex products, ensuring competitiveness across the product lifecycle.

Review the best moments of the Inauguration of the New Production Plant, for high potency products here.

Media
Bluepharma

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office

ONConcept April 2024

Our innovative nanoenzalutamide tablet development is strengthened by the recent decision of the European Patent Office to maintain Medivation/Astellas formulation patent EP3725778 B1...

Bluepharma

ONConcept® has successfully completed the pivotal BE study for Nilotinib

ONConcept January 2024

ONConcept® announces the successful completion of a positive bioequivalence (BE) study in the European Union for Nilotinib.The study marks a significant milestone in our commitment to...

Bluepharma

ONConcept® has successfully completed the pivotal BE study for Pomalidomide

ONConcept June 2023

Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area.

Bluepharma

Bluepharma opens an industrial unit unique in Portugal and one of the largest in Europe

ONConcept March 2023

Bluepharma, a Portuguese pharmaceutical company, has just opened a state-of-the-art industrial unit specialized in the production of oral solid high potent drugs, namely in the oncology area.

Bluepharma

How an Integrated European Hub for Complex Products is unlocking major market opportunities

Pharma Intelligence October 2022

The need for an integrated European developer and manufacturer of complex, differentiated and highly potent products is clearer than ever. Expirations on the patents and/or regulatory...

Bluepharma

ONConcept®: An Integrated European Hub for Delivering Highly Potent Complex Products

Pharma Intelligence July 2021

Off-patent, highly potent pharmaceuticals represent a major opportunity. The companies that seize the opportunity will grow sales by delivering products that improve the lives of patients...